Kamada Ltd. $KMDA Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC trimmed its holdings in Kamada Ltd. (NASDAQ:KMDA) by 9.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 255,631 shares of the biotechnology company’s stock after selling 27,073 shares during the period. Acadian Asset Management LLC owned 0.44% of Kamada worth $1,683,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Huntleigh Advisors Inc. purchased a new stake in shares of Kamada during the 1st quarter valued at about $863,000. Trexquant Investment LP bought a new position in Kamada in the first quarter worth about $82,000. Jane Street Group LLC bought a new position in shares of Kamada during the first quarter valued at approximately $582,000. Goldman Sachs Group Inc. bought a new position in shares of Kamada during the first quarter valued at approximately $497,000. Finally, NewEdge Advisors LLC grew its holdings in Kamada by 119.9% in the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after buying an additional 28,165 shares in the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Stock Up 2.9%

Shares of NASDAQ:KMDA opened at $7.03 on Wednesday. Kamada Ltd. has a 12-month low of $5.17 and a 12-month high of $9.15. The company has a market cap of $404.30 million, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 0.73 and a beta of 0.89. The company’s fifty day moving average is $7.30 and its two-hundred day moving average is $7.01.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Kamada Ltd. will post 0.23 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.00.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.